The degree of myocardial recovery determines the function and ultimately the survival of a
patient in cardiogenic shock. Therapeutic efforts to improve myocardial function include …

Abstract Treatment strategies to combat cardiogenic shock (CS) have remained stagnant
over the past decade. Mortality rates among patients who suffer CS after acute myocardial …

Cardiovascular mechanical circulatory support (MCS) offers the promise of forward blood
flow maintenance and distal tissue perfusion without taxing the failing heart. However, there …

Opinion statement Cardiogenic shock is a life-threatening presentation of severe heart
failure with high morbidity and mortality. Given the modest increased in cardiac output and …

Mechanical circulatory support (MCS) has made rapid progress over the last 3 decades.
This was driven by the need to develop acute and chronic circulatory support as well as by …

In other chapters, there are detailed discussions of acute decompensated heart failure
(Chap. 19) and shock (Chap. 21). Cardiogenic shock (CS) represents a state in which …

Cardiogenic shock (CS) has a high (~ 40%–50%) in-hospital mortality rate that has largely
remained unchanged for more than a decade 1, 2. Several percutaneous mechanical …

Randomized controlled trials have been difficult to conduct in this patient population; until
such trials are performed, implementing shock teams and protocols has been associated …

Abstract Purpose of Review In recent decades, multiple left and right ventricular assist
devices (VAD) have been developed, and the utilization of these devices has grown …

Use of mechanical devices to support the heart and circulation in patients in cardiogenic
shock is increasing. Dramatic results have been seen in patients in extremis, but …